Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04VXP
|
|||
| Former ID |
DNC010253
|
|||
| Drug Name |
4-(piperazin-1-yl)furo[3,2-c]pyridine
|
|||
| Synonyms |
4-(piperazin-1-yl)furo[3,2-c]pyridine; 81078-84-4; 4-PIPERAZIN-1-YL-FURO[3,2-C]PYRIDINE; 1-{furo[3,2-c]pyridin-4-yl}piperazine; CHEMBL595555; Furo[3,2-c]pyridine, 4-(1-piperazinyl)-; AK-76639; CHEMBL543969; PubChem17312; AC1MDRY3; SCHEMBL1026755; KS-00000EXO; CTK5E8449; DTXSID10383432; MolPort-000-145-249; LUIZVTKJWSGSPA-UHFFFAOYSA-N; ZINC4287704; 4-piperazinylfurano[3,2-c]pyridine; ANW-49259; BDBM50016972; SBB093149; 4-piperazin-1-ylfuro[3,2-c]pyridine; AKOS015919593; FS-3269; 1-(4-furo[3,2-c]pyridinyl)piperazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13N3O
|
|||
| Canonical SMILES |
C1CN(CCN1)C2=NC=CC3=C2C=CO3
|
|||
| InChI |
1S/C11H13N3O/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2
|
|||
| InChIKey |
LUIZVTKJWSGSPA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 81078-84-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2C receptor (HTR2C) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.